Brain 17 Vienna

07.11.2017

Proposed format & overarching goal

Community Surveys (SNO & ISN)

• Layer 1: Morphological classification

• Layer 2: WHO grade (reflects natural tumor history)

CAVE Diagnostic delay

• Layer 3: Molecular information

Integrated diagnosis

• Adds a level of objectivity to the diagnostic process

Surveys provided overwhelmingly positive feedback

• Stratifies tumors into biologically homogenous groups

• Enhances diagnostic accuracy & prognostic rating

NeuroOncol. 2016;19:336-344.

7

8

Classification based on histology & genetics

How many brain tumor entities are differentiated according to the WHO 2016 classification?

• International collaboration of 117 contributors from 20 countries

• Three-day consensus conference by a working group of 35 neuropathologists, clinical advisors and scientists from 10 countries

• A1. 1-30

• A2. 40-70

A4 is correct

• A3. 80-110

• A4. 120+

Austrian contributors: Johannes A. Hainfellner Matthias Preusser

9

10

2007

2016

Diffuse astrocytomas more similar to oligodendrogliomas than pilocytic astrocytomas -> family trees redrawn Gliomatosis cerebri deleted (invasive growth of diffuse astrocytoma, oligodendroglioma or glioblastoma)

WHO grading II-III retained

Diffuse astrocytoma categories: IDH-mutant IDH-wildtype NOS

Molecular markers now mandatory IDH, 1p19q, H3K27

11

12

2